On March 15, 2023 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported that the Company’s management team will participate in a virtual presentation at Oppenheimer’s 33rd Annual Healthcare Conference being held March 13-17, 2023 (Press release, Actinium Pharmaceuticals, MAR 15, 2023, View Sourcenews/detail/439/actinium-pharmaceuticals-inc-to-present-at-oppenheimers-33rd-annual-healthcare-conference" target="_blank" title="View Sourcenews/detail/439/actinium-pharmaceuticals-inc-to-present-at-oppenheimers-33rd-annual-healthcare-conference" rel="nofollow">View Source [SID1234628774]). The presentation will include recent Company highlights including positive results from its pivotal Phase 3 SIERRA trial of Iomab-B and development opportunities for Actimab-A under the recently signed Cooperative Research and Development Agreement with the National Cancer Institute (NCI).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast Information
Date & Time: March 15, 2023, 2:40 PM ET
Webcast Link: View Source

A replay of the presentation will be available on the Company’s IR section of the website for 90 days after the event: View Source